博拓生物
(688767)
| 流通市值：61.14亿 | | | 总市值：61.14亿 |
| 流通股本：1.49亿 | | | 总股本：1.49亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 214,684,129.57 | 89,376,734.08 | 448,012,337.89 | 308,071,086.61 |
| 营业收入 | 214,684,129.57 | 89,376,734.08 | 448,012,337.89 | 308,071,086.61 |
| 二、营业总成本 | 236,469,943.71 | 103,998,265.43 | 415,659,935.1 | 290,697,562.31 |
| 营业成本 | 113,664,093.39 | 46,871,801.51 | 241,784,295.48 | 165,483,214.53 |
| 税金及附加 | 2,716,836.23 | 1,789,569.27 | 8,381,523.89 | 6,392,314.2 |
| 销售费用 | 15,845,016.3 | 7,074,785.7 | 38,301,313.93 | 30,527,156.8 |
| 管理费用 | 32,704,396.79 | 16,303,409.4 | 59,337,452.27 | 49,075,972.7 |
| 研发费用 | 51,217,072.05 | 21,667,249.89 | 83,480,812.63 | 57,682,126.97 |
| 财务费用 | 20,322,528.95 | 10,291,449.66 | -15,625,463.1 | -18,463,222.89 |
| 其中:利息费用 | 189,809.12 | - | - | - |
| 其中:利息收入 | 16,596,895.46 | 8,604,291.66 | 38,271,318.16 | 29,254,544.82 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 353,518.3 | 122,764.95 | 320,319.1 | - |
| 加:投资收益 | -1,554,820.42 | -1,071,352.28 | 3,969,405.85 | 3,208,492.19 |
| 资产处置收益 | -8,531.25 | -12,988.22 | 247,488.75 | 259,027.54 |
| 资产减值损失(新) | -1,959,553.85 | -677,481.74 | -5,763,033.17 | -1,136,830.57 |
| 信用减值损失(新) | -818,189.03 | -128,920.64 | 236,841.77 | 579,410.06 |
| 其他收益 | 1,683,659.11 | 1,746,631.05 | 19,161,459.81 | 2,412,982.14 |
| 四、营业利润 | -24,089,731.28 | -14,642,878.23 | 50,524,884.9 | 22,696,605.66 |
| 加:营业外收入 | 609,077.93 | 226,349.81 | 72,564.57 | 54,500.23 |
| 减:营业外支出 | 141,987.07 | 7,311.41 | 915,782.36 | 19,153.51 |
| 五、利润总额 | -23,622,640.42 | -14,423,839.83 | 49,681,667.11 | 22,731,952.38 |
| 减:所得税费用 | -6,528,120.74 | -3,891,602.13 | 2,554,832.19 | 2,344,324.26 |
| 六、净利润 | -17,094,519.68 | -10,532,237.7 | 47,126,834.92 | 20,387,628.12 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -17,094,519.68 | -10,532,237.7 | 47,126,834.92 | 20,387,628.12 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -16,552,564.41 | -10,207,874.77 | 49,253,408.24 | 22,263,234.52 |
| 少数股东损益 | -541,955.27 | -324,362.93 | -2,126,573.32 | -1,875,606.4 |
| 扣除非经常损益后的净利润 | -20,801,885.17 | -12,946,986.22 | 27,001,186.21 | 15,095,737.55 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.11 | -0.07 | 0.34 | 0.14 |
| (二)稀释每股收益 | -0.11 | -0.07 | 0.34 | 0.14 |
| 八、其他综合收益 | 754,523.45 | 302,036.41 | 297,744.75 | 1,082,332.56 |
| 归属于母公司股东的其他综合收益 | 751,864.63 | 300,589.89 | 295,932.41 | 1,080,696 |
| 九、综合收益总额 | -16,339,996.23 | -10,230,201.29 | 47,424,579.67 | 21,469,960.68 |
| 归属于母公司股东的综合收益总额 | -15,800,699.78 | -9,907,284.88 | 49,549,340.65 | 23,343,930.52 |
| 归属于少数股东的综合收益总额 | -539,296.45 | -322,916.41 | -2,124,760.98 | -1,873,969.84 |
| 公告日期 | 2026-08-29 | 2026-04-25 | 2026-04-25 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |